Keywords
RNA-seq
Differentially expressed genes
Functional enrichment
Protein-protein interaction
Immunity
Submitted : 2024-01-23
Accepted : 2024-02-07
Published : 2024-02-22
Abstract
Objective: To identify potential drug targets for metastasis colorectal cancer (CRC) patients with low mutational burden by examining differences in immune-related gene expression. Methods: For this study, 623 samples were collected from The Cancer Genome Atlas (TCGA) database, comprising tumor mutational burden (TMB), RNA sequencing (RNA-Seq), and clinical data. Differential gene expression analysis, Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis of the identified genes were conducted using the R package. Additionally, a comparative analysis of immune infiltrating cell composition in metastatic and non-metastatic groups was performed. Hub genes, exhibiting high levels of interaction, were selected using the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database. The Drug Gene Interaction Database (DGIdb) was then utilized to estimate drugs targeting the identified hub genes. Results: The transcriptome data of 326 colorectal cancer patients with low TMB were analyzed, comprising 58 patients with metastasis and 268 patients without metastasis. Among the differential expression in 1,111 genes for patients with metastasis compared to those without metastasis, 733 genes were upregulated, and 378 genes were downregulated. KEGG and GO enrichment analysis indicated significant differences in gene expression in CRC metastatic patients with low TMB compared to non-metastasis patients with low TMB. Enriched pathways included humoral immuneresponse, immunoglobulin production, and regulation of AMPA receptor activity. Two genes related to interleukin-12 were identified through secondary enrichment for immune-related genes. Analysis of tumor-infiltrating immune cell data revealed significant differences in memory-activated T cell CD4 and T cell CD8. Conclusions: This analysis of RNA sequencing data and immune-filtrating cell data revealed significant differences between metastatic colorectal cancer patients with low TMB and their non-metastatic counterparts. These distinctions suggest the possibility of identifying more effective drugs or therapies for metastatic colorectal cancer patients with low TMB.
References
Keum N, Giovannucci E, 2019, Global Burden of Colorectal Cancer: Emerging Trends, Risk Factors and Prevention Strategies. Nat Rev Gastroenterol Hepatol, 16(12): 713–732. https://doi.org/10.1038/s41575-019-0189-8
Li Z, Chen Y, Ren WU, et al., 2019, Transcriptome Alterations in Liver Metastases of Colorectal Cancer After Acquired Resistance to Cetuximab. Cancer Genomics Proteomics, 16(3): 207–219. https://doi.org/10.21873/cgp.20126
Kikuchi T, Mimura K, Okayama H, et al., 2019, A Subset of Patients with MSS/MSI-Low-Colorectal Cancer Showed Increased CD8(+) TILs Together with Up-Regulated IFN-Gamma. Oncol Lett, 18(6): 5977–5985. https://doi.org/10.3892/ol.2019.10953
Picard E, Verschoor CP, Ma GW, et al., 2020, Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer. Front Immunol, 11: 369. https://doi.org/10.3389/fimmu.2020.00369
Chalmers ZR, Connelly CF, Fabrizio D, et al., 2017, Analysis of 100,000 Human Cancer Genomes Reveals the Landscape of Tumor Mutational Burden. Genome Med, 9(1): 34. https://doi.org/10.1186/s13073-017-0424-2
Roudko V, Bozkus CC, Orfanelli T, et al., 2020, Shared Immunogenic Poly-Epitope Frameshift Mutations in Microsatellite Unstable Tumors. Cell, 183(6): 1634–1649.e1617. https://doi.org/10.1016/j.cell.2020.11.004
Sha D, Jin Z, Budczies J, et al., 2020, Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors. Cancer Discov, 10(12): 1808–1825. https://doi.org/10.1158/2159-8290.CD-20-0522
McGrail DJ, Pilié PG, Rashid NU, et al., 2021, High Tumor Mutation Burden Fails to Predict Immune Checkpoint Blockade Response Across All Cancer Types. Ann Oncol, 32(5): 661–672. https://doi.org/10.1016/j.annonc.2021.02.006
Zehir A, Benayed R, Shah RH, et al., 2017, Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients. Nat Med, 23(6): 703–713. https://doi.org/10.1038/nm.4333
Valero C, Lee M, Hoen D, et al., 2021, The Association Between Tumor Mutational Burden and Prognosis is Dependent on Treatment Context. Nat Genet, 53(1): 11–15. https://doi.org/10.1038/s41588-020-00752-4
Gromeier M, Brown MC, Zhang G, et al., 2021, Very Low Mutation Burden is a Feature of Inflamed Recurrent Glioblastomas Responsive to Cancer Immunotherapy. Nat Commun, 12: 352. https://doi.org/10.1038/s41467-020-20469-6
DiGuardo MA, Davila JI, Jackson RA, et al., 2021, RNA-Seq Reveals Differences in Expressed Tumor Mutation Burden in Colorectal and Endometrial Cancers with and without Defective DNA-Mismatch Repair. J Mol Diagn, 23(5): 555–564. https://doi.org/10.1016/j.jmoldx.2021.01.008
Wu L, Yao H, Chen H, et al., 2022, Landscape of Somatic Alterations in Large-Scale Solid Tumors from an Asian Population. Nat Commun, 13(1): 4264. https://doi.org/10.1038/s41467-022-31780-9
Stepulak A, Sifringer M, Rzeski W, et al., 2007, AMPA Antagonists Inhibit the Extracellular Signal Regulated Kinase Pathway and Suppress Lung Cancer Growth. Cancer Biol Ther, 6(12): 1908–1915. https://doi.org/10.4161/cbt.6.12.4965
Ruiz DS, Luksch H, Sifringer M, et al., 2018, AMPA Receptor Antagonist CFM-2 Decreases Survivin Expression in Cancer Cells. Anticancer Agents Med Chem, 18(4): 591–596. https://doi.org/10.2174/1871520618666180228123406
Tewari D, Bawari S, Sharma S, et al., 2021, Targeting the Crosstalk Between Canonical Wnt/Beta-Catenin andInflammatory Signaling Cascades: A Novel Strategy for Cancer Prevention and Therapy. Pharmacol Ther, 227: 107876. https://doi.org/10.1016/j.pharmthera.2021.107876
Lee SC, Kim O-H, Lee SK, et al., 2015, IWR-1 Inhibits Epithelial-Mesenchymal Transition of Colorectal Cancer Cells Through Suppressing Wnt/?-Catenin Signaling as well as Survivin Expression. Oncotarget, 6(29): 27146–27159. https://doi.org/10.18632/oncotarget.4354
Tam BY, Chiu K, Chung H, et al., 2020, The CLK Inhibitor SM08502 Induces Anti-Tumor Activity and Reduces Wnt Pathway Gene Expression in Gastrointestinal Cancer Models. Cancer Lett, 473: 186–197. https://doi.org/10.1016/j.canlet.2019.09.009
Kumar B, Ahmad R, Sharma S, et al., 2021, PIK3C3 Inhibition Promotes Sensitivity to Colon Cancer Therapy by Inhibiting Cancer Stem Cells. Cancers (Basel), 13(9): 2168. https://doi.org/10.3390/cancers13092168
Bhattacharya D, Gawali VS, Kallay L, et al., 2021, Therapeutically Leveraging GABAA Receptors in Cancer. Exp Biol Med (Maywood), 246(19): 2128–2135. https://doi.org/10.1177/15353702211032549
Takehara A, Hosokawa M, Eguchi H, et al., 2007, Gamma-Aminobutyric Acid (GABA) Stimulates Pancreatic Cancer Growth Through Overexpressing GABAA Receptor Pi Subunit. Cancer Res, 67(20): 9704–9712.
Zhang B, Vogelzang A, Miyajima M, et al., 2021, B Cell-Derived GABA Elicits IL-10+ Macrophages to Limit AntiTumor Immunity. Nature, 599: 471–476. https://doi.org/10.1038/s41586-021-04082-1
Mirlekar B, Pylayeva-Gupta Y, 2021, IL-12 Family Cytokines in Cancer and Immunotherapy. Cancers (Basel), 13(2): 167. https://doi.org/10.3390/cancers13020167
Glassman CR, Mathiharan YK, Jude KM, et al., 2021, Structural Basis for IL-12 and IL-23 Receptor Sharing Reveals a Gateway for Shaping Actions on T versus NK Cells. Cell, 184(4): 983–999.e924. https://doi.org/10.1016/j.cell.2021.01.018
Zhang Y, Zhang Z, 2020, The History and Advances in Cancer Immunotherapy: Understanding the Characteristics of Tumor-Infiltrating Immune Cells and Their Therapeutic Implications. Cell Mol Immunol, 17(8): 807–821.